

NOVEMBER 8, 2014– NOVEMBER 14, 2014

## MEDIA NEWS + TRENDS

This weekly e-letter will highlight important media reports and call out any key trends that demonstrate how the landscape is evolving and accelerating in today's market environment. The update will also highlight action that has been initiated by OPPI in media.

### WEEKLY SNAPSHOT




### Need to know

- DIPP seeks public comments on proposed National IPR policy... [The Economic Times](#)
- US patent lobby to meet Indian judiciary, patent officials: Conflict of interest?... [The Times of India](#)
- Indian drug companies eye global brand buys to storm US market... [The Economic Times](#)
- Indian pharma to get boost with rise in affordable healthcare: report... [Mint](#)
- US lobbyists lose fire ahead of trade intellectual property review... [The Hindu Business Line](#)
- India, US IPR dialogue to begin this month... [Business Standard](#)
- Froman to lead India-US Trade Policy Forum meeting... [The Economic Times](#)
- Modi's Cabinet rejig: Insurance for all top priority for health ministry... [The Times of India](#)
- Will adopt holistic approach for improved healthcare: Health Minister J P Nadda... [The Economic Times](#)



### Good to know

- 'India's FDI regime is among most liberal in world today'... [Moneycontrol](#)
- Allocation of Portfolios amongst the members of the Council of Ministers... [PIB](#)
- Out of health ministry in just 5 months, Harsh Vardhan takes charge of science and tech ministry... [The Times of India](#)
- Pharma Trade Group Head Causes a Stir With a Remark About Patents... [The Wall Street Journal](#)
- NRIs filed 78% of the patent pleas in India... [The Times of India](#)
- Modi govt needs to ensure IPR policy safeguards India's interests, not US Inc's... [First Post](#)
- 10 years of Grand Challenges have little to show for \$1 billion spending... [Mint](#)
- Submissions made to the USTR on robustness of India's IP regime... [SpicyIP](#)
- Indian drug makers see US sales hit by delay in new approvals... [Mint](#)
- Shri Shripad Naik takes charge as MoS (IC), AYUSH and MoS, Health & Family Welfare... [Business Standard](#)



### Want to know

- Govt plans to inject life into sick PSU drug makers... [The Times of India](#)
- CIPLA VERSUS NOVARTIS... [Pharmabiz](#)
- 'We are not taking any chances': Harsh Vardhan... [Frontline](#)
- Big diplomatic victory: India rejoices as US takes a u-turn on WTO; Washington backs stand on food security... [The Economic Times](#)
- A sharp indictment of India's health system... [The Economic Times](#)
- Assoc of Medical Consultants writes an open letter to Dept of Health & Family Welfare on proposed amendments to MTP Act 1971... [DNA](#)
- Indian Healthcare Providers to Spend \$1.1 Billion on IT in 2014: Gartner... [NDTV](#)
- Indigenous way to eradicate diseases: NK Ganguly, former Director General, ICMR... [The Pioneer](#)
- Pneumonia & diarrhoea killed over 3 lakh kids in India in 2013: Report... [The Economic Times](#)
- S&P's report says India pharma cos are well positioned for global growth... [Pharmabiz](#)

---

## QUOTE OF THE WEEK

“Innovation and intellectual property rights are at the core of our industry. There is zero evidence that IP is a hindrance to access to medicines. We feel part of the debate is influenced by industrial policy considerations rather than patient access. Access goes beyond the mere supply and availability of drugs and medicines... I want to reiterate the importance of strong intellectual property rights frameworks as an enabler for innovation and access. There are “enormous challenges” for global health despite great gains, challenges such as 1.3 billion people with no access to effective and affordable health care, and the fact that more than 96 percent of medicines on the WHO Essential Drugs List are off-patent, fewer than 45 percent are accessible by patients who need them most, in markets where resources are most constrained. It is clear that IP is not the problem but part of the solution.”

- Stefan Oschmann, member of the Executive Board and CEO Pharma at Merck (Germany)...  
[\(Intellectual Property Watch\)](#)
-